Reports indicate that weight-loss drugs, including GLP-1, are having an impact on the fast-moving consumer goods (FMCG) industry. The effects of these health solutions are being observed in various regions, including Germany and the Nordic countries. The specifics of these changes and their broader implications for the FMCG market are being explored in various analyses and studies.